A very recent patent application from ASDERA on using hyproxypropyl-alfa-cyclodextrin formulated with a medium chain fatty acid (ideally a cproic acid derivative) for the ORAL delivery is the CD. Similarly to our interests, the CD itself is proposed to be the therapeutic agent and the oral delivery would open a new solution to treat cancer or a neurodegenerative, cardiovascular, metabolic, inflammatory, autoimmune, age-related, or viral disease or disorder in a subject which is currently only possible via parenteral administration. Keep an eye on Knut M. Wittkowski as his research is highly important. Overcoming the current issues with CD dosing is an unsolved problem in this research area.
See the full patent here: Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation
